MPNs highlights at EHA 2020: clinical trials, novel therapies & pitfalls

It is an exciting time in terms of therapeutic progress for myeloproliferative neoplasms (MPN). In recent years, there have been significant advances in the understanding of MPNs, including underlying genetic changes that drive the development of MPNs. This has led to research focusing on targeted therapy and increased the availability of new treatment options.
In this podcast, Srdan Verstovsek, MD, PhD, of the University of Texas MD Anderson Cancer Center, Houston, TX, Claire Harrison, MD, DM, FRCP, FRCPath, of Guy’s and St Thomas’ NHS Foundation Trust, London, UK, and Abdulraheem Yacoub, MD, of the University of Kansas Medical Center, Kansas City, MO, discuss key updates in the treatment and management of MPNs from this year’s European Hematology Association (EHA) 2020 congress.

The post MPNs highlights at EHA 2020: clinical trials, novel therapies & pitfalls appeared first on VJHemOnc.